Sanofi

SAN

FR0000120578

Pharmaceuticals

Market Closed - Euronext Paris Other stock markets 09:05:08 17/07/2024 pm IST			5-day change	1st Jan Change
92.02 ^EUR	+0.11%		-1.64%	+2.52%

17/07	Sanofi to invest $437 million in India global centre, double its workforce	RE
17/07	EU court criticizes Commission over handling of COVID vaccine contracts	RE

SANOFI : JP Morgan remains its Buy rating

January 04, 2021 at 05:23 pm IST

Analyst Richard Vosser from JP Morgan research considers the stock attractive and recommends it with a Buy rating. Previously set at EUR 100, the target price is lowered to EUR 93.

Latest news about Sanofi

Sanofi to invest $437 million in India global centre, double its workforce	17/07	RE
EU court criticizes Commission over handling of COVID vaccine contracts	17/07	RE
SANOFI : JP Morgan remains Neutral	16/07	ZD
Novo Nordisk faces scrutiny on Capitol Hill for pulling Levemir insulin from US market	13/07	RE
Goldman Sachs, Morgan Stanley Among Banks Lining Up $6.5 Billion Debt Financing for Sanofi Consumer Sale	12/07	MT
Banks Including Goldman Sachs, Morgan Stanley Lining Up $6.5 Billion Debt Financing for Sanofi Consumer Sale, Bloomberg Reports	12/07	MT
US Senator Sanders optimistic Novo Nordisk can be pressured to cut Wegovy, Ozempic prices	11/07	RE
Sanofi Ships U.S. Influenza Vaccines for the 2024/25 Season	11/07	CI
SANOFI : Receives a Sell rating from Deutsche Bank	10/07	ZD
SANOFI : UBS reiterates its buy recommendation	09/07	CF
Sector Update: Health Care Stocks Flat to Higher Premarket Tuesday	09/07	MT
SANOFI : UBS maintains a Buy rating	09/07	ZD
Kymera Reports Expansion of KT-474 Trials; Shares Rise After-Hours	09/07	MT
Kymera Therapeutics, Inc. Announces Expansion of KT-474 HS and AD Phase 2 Studies Following Interim Review of Safety and Efficacy	09/07	CI
SANOFI : Jefferies maintains a Buy rating	08/07	ZD
SANOFI : Stifel slightly raises its target on the stock	08/07	CF
That's not so bad, is it?	08/07
Sector Update: Health Care Stocks Steady Premarket Friday	05/07	MT
Sector Update: Health Care	05/07	MT
GlaxoSmithkline Pharmaceuticals Limited Announces Change in Management	05/07	CI
Sanofi's Consumer Health Unit Receives Interest from French State	05/07	MT
Bpifrance eyes investment in Sanofi's consumer health business	04/07	RE
Bain Capital, Cinven, Others Said Mulling Bids for Sanofi's Consumer Health Unit	04/07	MT
Bain, Cinven Explore Joint Bid for Sanofi's Consumer Unit, Bloomberg Reports	04/07	DJ
Paul Hudson, CEO of Sanofi: AI to improve organisational efficiency	04/07	MT

Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (70.6%): prescription drugs in the areas of specialty medicine (59.3% of net sales; for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases) and general medicine (40.7%; mainly for the treatment of diabetes and cardiovascular diseases); - human vaccines (17.4%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas; - consumer health products (12%). At the end of 2023, the group had 54 production sites throughout the world. Net sales are distributed geographically as follows: France (5.5%), Europe (18.6%), the United States (43%), North America (1.6%) and other (31.3%).

Sector

Pharmaceuticals

Calendar

25/07/2024 - Q2 2024 Earnings Release

Related indices

CAC 40 , Euro STOXX 50 Index , STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Paul Hudson, CEO of Sanofi: AI to improve organisational efficiency

July 04, 2024 at 01:31 am IST

SANOFI : Sanofi’s healthy Q1 performance hailed by markets

April 25, 2024 at 05:28 pm IST

Sanofi : In the hot seat

October 30, 2023 at 04:22 pm IST

More Strategies

Ratings for Sanofi

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

92.02 EUR

Average target price

108.6 EUR

Spread / Average Target

+17.97%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SANOFI	+2.52%	13TCr
ELI LILLY AND COMPANY	+55.35%	85TCr
NOVO NORDISK A/S	+31.64%	63TCr
JOHNSON & JOHNSON	-0.10%	36TCr
MERCK & CO., INC.	+15.47%	32TCr
ABBVIE INC.	+13.10%	30TCr
ASTRAZENECA PLC	+15.51%	24TCr
NOVARTIS AG	+16.72%	23TCr
AMGEN INC.	+16.54%	18TCr
PFIZER, INC.	+4.31%	17TCr

Other Pharmaceuticals

Sanofi

Equities

SAN

FR0000120578

Pharmaceuticals

SANOFI : JP Morgan remains its Buy rating

Latest news about Sanofi

Chart Sanofi

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Sanofi

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals